Skip to content
  • Products and Services
  • News and Journals
  • About Us
Contact Us
  • Nov 27, 2018
  • Publications

Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research

Cancer has recently surpassed cardiovascular diseases as the leading cause of death worldwide. The increasing cancer incidence combined with the emergence of improved therapeutic strategies has driven research into fields such as how the immune system Influences cancer development and progression. This article reviews various animal models, and explains the benefits of porcine-based preclinical research.

Share this article:

LinkedIn
Facebook
Twitter

More articles

Featured Sus Clinicals Events at SBR 2024
Company news
Sus Clinicals to Present at Society of Interventional Radiology (SIR)…
Company news
Oncopig bladder cancer cells recapitulate human bladder cancer treatment responses…
Publications
Sus Clinicals Appoints Dr. Lawrence Schook to Board of Directors
Press release
Presentation at SIO 2024
Company news
Sus Clinicals, Inc. Announces $2 Million Research Grant from the…
Press release
Sus Clinicals, Inc. Announces Former Jackson Labs Executive Joins the…
Press release
Effect of CRISPR Knockout of AXIN1 or ARID1A on Proliferation…
Publications
Sus Clinicals, Inc. Announces Formation of Advisory Council
Press release
Sus Clinicals Announces Former McKinsey Executive Joins the Company as…
Press release
Sus Clinicals, Inc. Receives Clearance from the U.S. Food &…
Press release
Porcine Cancer Models: Potential Tools to Enhance Cancer Drug Trials
Publications

Subscribe to our newsletter

Stay connected

Linkedin Youtube X-twitter Facebook Envelope
Book a meeting
Meet with Sus Clinicals at AACR

The American Association for Cancer Research (AACR) Annual Meeting will take place April 25-30 at the McCormick Place Convention Center in Chicago, IL.

Our team is actively partnering with CROs, device developers, pharma., and research institutions to support oncology research, device validation, and translational development through our Oncopig model—a versatile platform for large animal studies across a variety of tumor types. More information is on the event page.

Our CEO and VP of R&D and Services will be in attendance and would love to connect with you. We invite you to book a meeting at the link below or reach out on our website.

click Me